Jiangsu Hengrui Medicine (China)

Gold Nanoparticle-Enabled Cancer Therapy: Translational Design Rules for Photothermal–Immunotherapy and Multimodal Precision Oncology

Gold nanoparticles (AuNPs) are versatile cancer-therapy platforms with tunable plasmonic properties, high atomic number, accessible surface chemistry, and potential for integration into theranostic systems. By controlling size, morphology, surface composition, and cargo-loading s...

Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist

ABSTRACT Aims This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors....

52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial

BACKGROUND: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To describe efficacy and safety outcomes through Week 52. METHODS: In this multicentr...

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression

PURPOSE Systemic treatment options for advanced salivary gland carcinoma (SGC) are limited, and prospective data for human epidermal growth factor receptor 2 (HER2)–directed therapy remain sparse, particularly in HER2-low disease. We evaluated trastuzumab rezetecan (SHR-A1811), a...

An ELISA‐Inspired Self‐Propagating Click‐Fluoresce‐and‐Release Assay for the Ultrasensitive Detection of CD13 in Lung Cancer Patient Plasma

ABSTRACT Reaction‐based fluorescent probes often suffer from limited sensitivity in biomarker detection due to slow reaction kinetics and inherent stoichiometric constraints. Inspired by the decoupling of capture and detection in the enzyme‐linked immunosorbent assay (ELISA), we...

An ELISA‐Inspired Self‐Propagating Click‐Fluoresce‐and‐Release Assay for the Ultrasensitive Detection of CD13 in Lung Cancer Patient Plasma

ABSTRACT Reaction‐based fluorescent probes often suffer from limited sensitivity in biomarker detection due to slow reaction kinetics and inherent stoichiometric constraints. Inspired by the decoupling of capture and detection in the enzyme‐linked immunosorbent assay (ELISA), we...